1. Home
  2. MNPR vs VINP Comparison

MNPR vs VINP Comparison

Compare MNPR & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$70.28

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

N/A

Current Price

$8.26

Market Cap

601.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MNPR
VINP
Founded
2014
2009
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
601.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MNPR
VINP
Price
$70.28
$8.26
Analyst Decision
Strong Buy
Buy
Analyst Count
12
6
Target Price
★ $130.17
$12.24
AVG Volume (30 Days)
127.0K
★ 133.5K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
★ 8.27%
EPS Growth
★ 54.99
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$21.39
Revenue Next Year
N/A
$11.29
P/E Ratio
★ N/A
$24.41
Revenue Growth
N/A
N/A
52 Week Low
$50.07
$8.10
52 Week High
$124.82
$13.61

Technical Indicators

Market Signals
Indicator
MNPR
VINP
Relative Strength Index (RSI) 42.77 32.70
Support Level $66.88 N/A
Resistance Level $75.33 $10.17
Average True Range (ATR) 4.74 0.43
MACD 0.73 -0.03
Stochastic Oscillator 51.81 10.00

Price Performance

Historical Comparison
MNPR
VINP

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

Share on Social Networks: